TNF and myeloid sarcoma: TNF has been proposed as a principal pro-inflammatory mediator in MS pathogenesis and its levels associated with disease progression, but, surprisingly, the systemic blockade of TNF in some MS patients led to immune activation and increased disease activity, as demonstrated by two clinical trials involving the use of antibody-based TNF antagonists in patients with demyelinating disease [31,32].